- Home
- ARQT
as 11-20-2024 4:00pm EST
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | WESTLAKE VILLAGE |
| Market Cap: | 1.1B | IPO Year: | 2020 |
| Target Price: | $14.40 | AVG Volume (30 days): | 2.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.73 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.76 - $13.17 | Next Earning Date: | 11-06-2024 |
| Revenue: | $138,708,000 | Revenue Growth: | 182.84% |
| Revenue Growth (this year): | 208.32% | Revenue Growth (next year): | 48.56% |
Stock Insider Trading Activity of Arcutis Biotherapeutics Inc. (ARQT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Matsuda Masaru | ARQT | See Remarks | Nov 18 '24 | Sell | $9.68 | 1,775 | $17,190.34 | 181,373 | |
| Burnett Patrick | ARQT | See Remarks | Nov 14 '24 | Sell | $10.21 | 69,226 | $712,620.61 | 128,669 | |
| Matsuda Masaru | ARQT | See Remarks | Nov 4 '24 | Sell | $8.68 | 5,015 | $43,551.26 | 181,373 | |
| Burnett Patrick | ARQT | See Remarks | Nov 4 '24 | Sell | $8.68 | 15,441 | $134,092.73 | 128,669 | |
| Watanabe Todd Franklin | ARQT | See Remarks | Nov 4 '24 | Sell | $8.68 | 13,871 | $120,458.54 | 832,392 | |
| Welgus Howard G. | ARQT | Director | Nov 1 '24 | Sell | $8.65 | 10,000 | $86,541.00 | 171,944 | |
| Edwards Larry Todd | ARQT | SVP Chief Commercial Officer | Oct 2 '24 | Sell | $10.01 | 3,725 | $37,295.45 | 136,635 | |
| Welgus Howard G. | ARQT | Director | Oct 1 '24 | Sell | $9.26 | 10,000 | $92,616.00 | 171,944 | |
| Topper David Joseph | ARQT | Chief Financial Officer | Sep 21 '24 | Sell | $9.48 | 11,626 | $110,264.47 | 158,374 | |
| Welgus Howard G. | ARQT | Director | Sep 3 '24 | Sell | $10.77 | 10,000 | $107,695.00 | 171,944 |
Latest Arcutis Biotherapeutics Inc. News
ARQT Breaking Stock News: Dive into ARQT Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 200-Day Moving Average
Zacks
a day ago
Arcutis Biotherapeutics, Inc. (ARQT) Crossed Above the 50-Day Moving Average: What That Means for Investors
Zacks
2 days ago
Bears are Losing Control Over Arcutis Biotherapeutics (ARQT), Here's Why It's a 'Buy' Now
Zacks
2 days ago
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average
GlobeNewswire
8 days ago
Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour
Zacks
10 days ago
Wall Street Analysts See a 70.33% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High?
Simply Wall St.
13 days ago
Arcutis Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations
GuruFocus.com
14 days ago
Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings Call Highlights: Robust Growth and ...
Compare ARQT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARQT Arcutis Biotherapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.